首页 > 最新文献

Reumatismo最新文献

英文 中文
Alfonse T. Masi. 阿方斯T。
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2025-02-13 DOI: 10.4081/reumatismo.2025.1892
Maurizio Cutolo

Alfonse T. Masi (born October 1930) passed away peacefully and comfortably in his home in March 2025 at the age of 94 years after a prestigious career...

阿方斯·t·马西(生于1930年10月)于2025年3月在他的家中平静而舒适地去世,享年94岁。
{"title":"Alfonse T. Masi.","authors":"Maurizio Cutolo","doi":"10.4081/reumatismo.2025.1892","DOIUrl":"10.4081/reumatismo.2025.1892","url":null,"abstract":"<p><p>Alfonse T. Masi (born October 1930) passed away peacefully and comfortably in his home in March 2025 at the age of 94 years after a prestigious career...</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":"77 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Italian Society for Rheumatology guidelines on reproductive health in patients with rheumatic diseases. 意大利风湿病学会关于风湿病患者生殖健康的指南。
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2025-02-13 Epub Date: 2025-02-12 DOI: 10.4081/reumatismo.2025.1752
Chiara Crotti, Nicola Ughi, Emanuela Beretta, Antonio Luca Brucato, Greta Carrara, Maria Sole Chimenti, Paola Conigliaro, Francesca Crisafulli, Giovanna Cuomo, Emma Di Poi, Khadija El Auofy, Micaela Fredi, Maria Chiara Gerardi, Maria Gerosa, Ariela Hoxa, Aurora Ianniello, Maddalena Larosa, Danila Morano, Marta Mosca, Mario Motta, Martina Orlandi, Melissa Padovan, Davide Rozza, Savino Sciascia, Silvia Tonolo, Simona Truglia, Maria Letizia Urban, Anna Zanetti, Sonia Zatti, Angela Tincani

Objective: To date, there is no shared national guideline in Italy for the management of reproductive health in rheumatic diseases (RHRD). The Italian Society for Rheumatology (SIR) has committed to developing clinical practice recommendations to provide guidance on both management and treatment regarding RHRD in Italy.

Methods: Using the GRADE-ADOLOPMENT methodology, a systematic literature review was conducted to update the scientific evidence that emerged after the publication of the reference recommendations from the American College of Rheumatology. A multidisciplinary group of 18 clinicians with specialist experience in rheumatology, allergy and clinical immunology, internal medicine, nephrology, gynecology and obstetrics, and neonatology, a professional nurse, a clinical psychologist, and a representative from the National Association of Rheumatic Patients discussed the recommendations in collaboration with the evidence review working group. Subsequently, a group of stakeholders was consulted to examine and externally evaluate the developed recommendations.

Results: Recommendations were formulated for each area of interest: contraception, assisted reproductive technology, preconception counseling, and use of drugs before, during, and after pregnancy and during breastfeeding, considering both paternal and maternal exposure.

Conclusions: The new SIR recommendations provide the rheumatology community with a practical guide based on updated scientific evidence for the management of RHRD.

目的:迄今为止,意大利尚无风湿病(RHRD)生殖健康管理的共同国家指南。意大利风湿病学会致力于制定临床实践建议,为意大利RHRD的管理和治疗提供指导。方法:采用GRADE-ADOLOPMENT方法,进行系统的文献综述,以更新美国风湿病学会参考建议发表后出现的科学证据。由18名具有风湿病学、过敏和临床免疫学、内科、肾脏病学、妇产科和新生儿学专业经验的临床医生、一名专业护士、一名临床心理学家和一名全国风湿病患者协会代表组成的多学科小组与证据审查工作组合作讨论了这些建议。随后,咨询了一组利益相关者,以检查和外部评估所制定的建议。结果:针对每个感兴趣的领域制定了建议:避孕,辅助生殖技术,孕前咨询,怀孕前,怀孕期间,怀孕后和母乳喂养期间的药物使用,考虑到父亲和母亲的暴露。结论:新的SIR建议为风湿病学界提供了基于最新科学证据的RHRD管理实用指南。
{"title":"The Italian Society for Rheumatology guidelines on reproductive health in patients with rheumatic diseases.","authors":"Chiara Crotti, Nicola Ughi, Emanuela Beretta, Antonio Luca Brucato, Greta Carrara, Maria Sole Chimenti, Paola Conigliaro, Francesca Crisafulli, Giovanna Cuomo, Emma Di Poi, Khadija El Auofy, Micaela Fredi, Maria Chiara Gerardi, Maria Gerosa, Ariela Hoxa, Aurora Ianniello, Maddalena Larosa, Danila Morano, Marta Mosca, Mario Motta, Martina Orlandi, Melissa Padovan, Davide Rozza, Savino Sciascia, Silvia Tonolo, Simona Truglia, Maria Letizia Urban, Anna Zanetti, Sonia Zatti, Angela Tincani","doi":"10.4081/reumatismo.2025.1752","DOIUrl":"10.4081/reumatismo.2025.1752","url":null,"abstract":"<p><strong>Objective: </strong>To date, there is no shared national guideline in Italy for the management of reproductive health in rheumatic diseases (RHRD). The Italian Society for Rheumatology (SIR) has committed to developing clinical practice recommendations to provide guidance on both management and treatment regarding RHRD in Italy.</p><p><strong>Methods: </strong>Using the GRADE-ADOLOPMENT methodology, a systematic literature review was conducted to update the scientific evidence that emerged after the publication of the reference recommendations from the American College of Rheumatology. A multidisciplinary group of 18 clinicians with specialist experience in rheumatology, allergy and clinical immunology, internal medicine, nephrology, gynecology and obstetrics, and neonatology, a professional nurse, a clinical psychologist, and a representative from the National Association of Rheumatic Patients discussed the recommendations in collaboration with the evidence review working group. Subsequently, a group of stakeholders was consulted to examine and externally evaluate the developed recommendations.</p><p><strong>Results: </strong>Recommendations were formulated for each area of interest: contraception, assisted reproductive technology, preconception counseling, and use of drugs before, during, and after pregnancy and during breastfeeding, considering both paternal and maternal exposure.</p><p><strong>Conclusions: </strong>The new SIR recommendations provide the rheumatology community with a practical guide based on updated scientific evidence for the management of RHRD.</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143410396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retrospective evaluation of the efficacy of ultrasound-guided intra-articular hyaluronic-acid-based injections (Hyalubrix®) in patients with glenohumeral osteoarthritis. 超声引导下关节内透明质酸注射(Hyalubrix®)治疗盂肱骨关节炎疗效的回顾性评价。
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2025-02-13 Epub Date: 2024-12-16 DOI: 10.4081/reumatismo.2024.1699
Lorenzo Monti, Emanuele Franchi, Francesco Verde, Stefano Sgherzi, Filippo Maria Anghilieri

Objective: Intra-articular injections of hyaluronic acid (HA) have been reported to alleviate pain, reduce disability, and improve joint function in glenohumeral osteoarthritis (GH-OA). This retrospective study aimed to evaluate the effectiveness of a HA-based formulation (Hyalubrix®) in reducing the pain of patients with GH-OA and improving both patient's shoulder functions and quality of life (QoL).

Methods: Data collected during the standard clinical practice of the center was retrospectively analyzed. The Simple Shoulder Test (SST) questionnaire reported data on the patient's ability to perform daily activities; the Euro-Quality of Life Health Assessment (EQ-5D) collected evidence on QoL; and changes in pain were evaluated through the Visual Analog Scale (VAS). SST and EQ-5D scores were analyzed comparing baseline values with those at the last follow-up, while VAS was investigated for all the available visits. Continuous values were summarized as mean ± standard deviation, median, and 25-75th percentiles. The Shapiro-Wilk test assessed normality, with significance set at p<0.05, and no adjustments for multiple comparisons were made.

Results: All scores showed a significant improvement: VAS decreased from 55.4±13.8 to 16.2±16.3 (p<0.001), the SST increased from 38.0 to 65.5 (p<0.001), as did the EQ-5D (from 41.7 to 76.7; p<0.001).

Conclusions: GH-OA treatment with Hyalubrix® proved to be highly beneficial, leading to complete pain reduction in more than 50% of patients and a significant reduction in 27.5% of cases. This resulted in improved joint function and QoL.

目的:据报道,关节内注射透明质酸(HA)可以减轻关节骨性关节炎(GH-OA)患者的疼痛、减少残疾和改善关节功能。本回顾性研究旨在评估ha制剂(Hyalubrix®)在减轻GH-OA患者疼痛、改善患者肩关节功能和生活质量(QoL)方面的有效性。方法:回顾性分析该中心在标准临床实践中收集的资料。简单肩部测试(SST)问卷报告了患者进行日常活动能力的数据;欧洲生活质量健康评估(EQ-5D)收集了生活质量的证据;通过视觉模拟评分(VAS)评估疼痛的变化。将基线值与最后一次随访时的SST和EQ-5D评分进行比较分析,并对所有可用的就诊进行VAS调查。连续值汇总为平均值±标准差、中位数和25-75百分位数。结果:所有评分均有显著改善:VAS从55.4±13.8降至16.2±16.3(结论:Hyalubrix®治疗GH-OA证明是非常有益的,超过50%的患者完全减轻疼痛,27.5%的病例显着减少。这改善了关节功能和生活质量。
{"title":"Retrospective evaluation of the efficacy of ultrasound-guided intra-articular hyaluronic-acid-based injections (Hyalubrix<sup>®</sup>) in patients with glenohumeral osteoarthritis.","authors":"Lorenzo Monti, Emanuele Franchi, Francesco Verde, Stefano Sgherzi, Filippo Maria Anghilieri","doi":"10.4081/reumatismo.2024.1699","DOIUrl":"10.4081/reumatismo.2024.1699","url":null,"abstract":"<p><strong>Objective: </strong>Intra-articular injections of hyaluronic acid (HA) have been reported to alleviate pain, reduce disability, and improve joint function in glenohumeral osteoarthritis (GH-OA). This retrospective study aimed to evaluate the effectiveness of a HA-based formulation (Hyalubrix®) in reducing the pain of patients with GH-OA and improving both patient's shoulder functions and quality of life (QoL).</p><p><strong>Methods: </strong>Data collected during the standard clinical practice of the center was retrospectively analyzed. The Simple Shoulder Test (SST) questionnaire reported data on the patient's ability to perform daily activities; the Euro-Quality of Life Health Assessment (EQ-5D) collected evidence on QoL; and changes in pain were evaluated through the Visual Analog Scale (VAS). SST and EQ-5D scores were analyzed comparing baseline values with those at the last follow-up, while VAS was investigated for all the available visits. Continuous values were summarized as mean ± standard deviation, median, and 25-75th percentiles. The Shapiro-Wilk test assessed normality, with significance set at p<0.05, and no adjustments for multiple comparisons were made.</p><p><strong>Results: </strong>All scores showed a significant improvement: VAS decreased from 55.4±13.8 to 16.2±16.3 (p<0.001), the SST increased from 38.0 to 65.5 (p<0.001), as did the EQ-5D (from 41.7 to 76.7; p<0.001).</p><p><strong>Conclusions: </strong>GH-OA treatment with Hyalubrix® proved to be highly beneficial, leading to complete pain reduction in more than 50% of patients and a significant reduction in 27.5% of cases. This resulted in improved joint function and QoL.</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142838440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors of poor outcomes in juvenile dermatomyositis: what do we know? A narrative review. 幼年皮肌炎不良预后的预测因素:我们知道些什么?叙述性综述。
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2025-02-13 Epub Date: 2024-11-11 DOI: 10.4081/reumatismo.2024.1640
Ana Martins, Sara Ganhão, Francisca Aguiar, Mariana Rodrigues, Iva Brito

Objective: Juvenile dermatomyositis (JDM) is a rare chronic systemic inflammatory disorder with a highly variable clinical course. It is important to identify the patients at risk of developing more severe disease. However, based on the existing literature, there is a lack of data regarding predictors of poor outcomes. Obtaining knowledge about clinical and laboratory risk factors for disease progression and severity at an earlier stage of the disease could potentially lead to a better long-term prognosis for patients with JDM.

Methods: A narrative review to identify risk factors for poor outcomes in patients with JDM, such as death, severe disease, refractory disease, and functional impairment, was conducted. A total of 27 articles were included.

Results: Certain clinical manifestations and immunology features appear to worsen the prognosis in children with JDM. The recognition of these risk factors is essential for all pediatric rheumatologists as it allows the earlier identification of patients with potentially worse outcomes. These patients should receive closer follow-up and aggressive and individualized therapy to reduce their morbimortality.

Conclusions: Additional research is needed not only to identify more predictors of worse outcomes but also more effective treatment approaches targeted toward these patients.

目的:幼年皮肌炎(JDM)是一种罕见的慢性全身性炎症性疾病,临床病程多变。识别有可能发展成更严重疾病的患者非常重要。然而,根据现有文献,有关不良预后预测因素的数据还很缺乏。在疾病的早期阶段获得有关疾病进展和严重程度的临床和实验室风险因素的知识,有可能为 JDM 患者带来更好的长期预后:方法:我们进行了一项叙事性综述,旨在确定JDM患者不良预后的风险因素,如死亡、严重疾病、难治性疾病和功能障碍。共纳入 27 篇文章:结果:某些临床表现和免疫学特征似乎会使JDM患儿的预后恶化。对于所有儿科风湿病专家来说,识别这些风险因素至关重要,因为这样可以及早发现预后可能较差的患者。这些患者应接受更密切的随访和积极的个体化治疗,以降低其死亡率:我们需要开展更多的研究,不仅要找出更多预示不良后果的因素,还要找出针对这些患者的更有效的治疗方法。
{"title":"Predictors of poor outcomes in juvenile dermatomyositis: what do we know? A narrative review.","authors":"Ana Martins, Sara Ganhão, Francisca Aguiar, Mariana Rodrigues, Iva Brito","doi":"10.4081/reumatismo.2024.1640","DOIUrl":"10.4081/reumatismo.2024.1640","url":null,"abstract":"<p><strong>Objective: </strong>Juvenile dermatomyositis (JDM) is a rare chronic systemic inflammatory disorder with a highly variable clinical course. It is important to identify the patients at risk of developing more severe disease. However, based on the existing literature, there is a lack of data regarding predictors of poor outcomes. Obtaining knowledge about clinical and laboratory risk factors for disease progression and severity at an earlier stage of the disease could potentially lead to a better long-term prognosis for patients with JDM.</p><p><strong>Methods: </strong>A narrative review to identify risk factors for poor outcomes in patients with JDM, such as death, severe disease, refractory disease, and functional impairment, was conducted. A total of 27 articles were included.</p><p><strong>Results: </strong>Certain clinical manifestations and immunology features appear to worsen the prognosis in children with JDM. The recognition of these risk factors is essential for all pediatric rheumatologists as it allows the earlier identification of patients with potentially worse outcomes. These patients should receive closer follow-up and aggressive and individualized therapy to reduce their morbimortality.</p><p><strong>Conclusions: </strong>Additional research is needed not only to identify more predictors of worse outcomes but also more effective treatment approaches targeted toward these patients.</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PASSing to the patient side: early achieving of an acceptable symptom state in patients with rheumatoid arthritis treated with Janus kinase inhibitors. PASS到患者一方:类风湿性关节炎患者接受 Janus 激酶抑制剂治疗后,尽早达到可接受的症状状态。
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2025-02-13 Epub Date: 2024-11-05 DOI: 10.4081/reumatismo.2024.1725
Cristina Garufi, Silvia Mancuso, Fulvia Ceccarelli, Letizia Caruso, Cristiano Alessandri, Manuela Di Franco, Roberta Priori, Valeria Riccieri, Rossana Scrivo, Simona Truglia, Fabrizio Conti, Francesca Romana Spinelli

Objective: Patients Acceptable Symptom State (PASS) is a single dichotomized question assessing health satisfaction. We aimed to investigate PASS achievement within 4 weeks of treatment with Janus kinase (JAK) inhibitors (Jakinibs) and its association with treatment response after 4 and 12 weeks in rheumatoid arthritis (RA) patients.

Methods: We recruited consecutive RA patients starting baricitinib or tofacitinib. At baseline, 4 and 12 weeks, we calculated disease activity [Disease Activity Score on 28 joints (DAS28), Clinical Disease Activity Index, Simplified Disease Activity Index], disease status [remission and low-disease activity (LDA)], percentage of patients achieving PASS, and the time to attain PASS. We assessed the impact of clinically relevant variables on PASS achievement by logistic regression analysis.

Results: We enrolled 113 patients [98 (86.7%) females; median age 59.6 (interquartile range 16.9), median disease duration 144 (132) months]. 90 (79.6%) patients achieved PASS after 10 (8) days. A similar percentage of PASS achievers and non-achievers was in remission/LDA at weeks 4 and 12, but the reduction of disease activity was significantly greater in PASS achievers. All patients achieving Boolean remission at weeks 4 and 12 had achieved PASS within 4 weeks. The impact of Patients Global Assessment (PGA) on DAS28 was significantly greater in PASS non-achievers compared to PASS achievers; inversely, the impact of C-reactive protein was more relevant in PASS achievers. At multivariate analysis, pain and PGA were significantly associated with PASS.

Conclusions: In our cohort, Jakinibs allowed an early achievement of PASS in a great percentage of RA patients. PASS is strictly dependent on PGA and pain and could suggest, early in the management of RA patients, therapeutic success.

目的:患者可接受症状状态(PASS)是一个评估健康满意度的单一二分法问题。我们旨在调查类风湿性关节炎(RA)患者在接受Janus激酶(JAK)抑制剂(Jakinibs)治疗4周内的PASS成就及其与4周和12周后治疗反应的关联:我们招募了开始使用巴利昔尼或托法替尼的连续 RA 患者。在基线、4周和12周时,我们计算了疾病活动度[28个关节的疾病活动度评分(DAS28)、临床疾病活动度指数、简化疾病活动度指数]、疾病状态[缓解和低疾病活动度(LDA)]、达到PASS的患者比例以及达到PASS的时间。我们通过逻辑回归分析评估了临床相关变量对达到 PASS 的影响:我们共招募了 113 名患者[98 名(86.7%)女性;中位年龄 59.6 岁(四分位数间距 16.9),中位病程 144(132)个月]。90(79.6%)名患者在 10(8)天后达到 PASS。在第 4 周和第 12 周,达到 PASS 的患者和未达到 PASS 的患者缓解/LDA 的比例相似,但达到 PASS 的患者疾病活动的减少幅度明显更大。所有在第 4 周和第 12 周达到布尔缓解的患者都在 4 周内达到了 PASS。未达到PASS的患者与达到PASS的患者相比,患者全面评估(PGA)对DAS28的影响明显更大;相反,C反应蛋白对达到PASS的患者的影响更大。在多变量分析中,疼痛和PGA与PASS明显相关:结论:在我们的队列中,Jakinibs能使很大一部分RA患者尽早达到PASS。PASS严格依赖于PGA和疼痛,可提示RA患者早期治疗的成功。
{"title":"PASSing to the patient side: early achieving of an acceptable symptom state in patients with rheumatoid arthritis treated with Janus kinase inhibitors.","authors":"Cristina Garufi, Silvia Mancuso, Fulvia Ceccarelli, Letizia Caruso, Cristiano Alessandri, Manuela Di Franco, Roberta Priori, Valeria Riccieri, Rossana Scrivo, Simona Truglia, Fabrizio Conti, Francesca Romana Spinelli","doi":"10.4081/reumatismo.2024.1725","DOIUrl":"10.4081/reumatismo.2024.1725","url":null,"abstract":"<p><strong>Objective: </strong>Patients Acceptable Symptom State (PASS) is a single dichotomized question assessing health satisfaction. We aimed to investigate PASS achievement within 4 weeks of treatment with Janus kinase (JAK) inhibitors (Jakinibs) and its association with treatment response after 4 and 12 weeks in rheumatoid arthritis (RA) patients.</p><p><strong>Methods: </strong>We recruited consecutive RA patients starting baricitinib or tofacitinib. At baseline, 4 and 12 weeks, we calculated disease activity [Disease Activity Score on 28 joints (DAS28), Clinical Disease Activity Index, Simplified Disease Activity Index], disease status [remission and low-disease activity (LDA)], percentage of patients achieving PASS, and the time to attain PASS. We assessed the impact of clinically relevant variables on PASS achievement by logistic regression analysis.</p><p><strong>Results: </strong>We enrolled 113 patients [98 (86.7%) females; median age 59.6 (interquartile range 16.9), median disease duration 144 (132) months]. 90 (79.6%) patients achieved PASS after 10 (8) days. A similar percentage of PASS achievers and non-achievers was in remission/LDA at weeks 4 and 12, but the reduction of disease activity was significantly greater in PASS achievers. All patients achieving Boolean remission at weeks 4 and 12 had achieved PASS within 4 weeks. The impact of Patients Global Assessment (PGA) on DAS28 was significantly greater in PASS non-achievers compared to PASS achievers; inversely, the impact of C-reactive protein was more relevant in PASS achievers. At multivariate analysis, pain and PGA were significantly associated with PASS.</p><p><strong>Conclusions: </strong>In our cohort, Jakinibs allowed an early achievement of PASS in a great percentage of RA patients. PASS is strictly dependent on PGA and pain and could suggest, early in the management of RA patients, therapeutic success.</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Conventional radiography and correlated factors of enthesopathies of the Achilles tendon and plantar fascia in patients with axial spondyloarthritis. 轴性脊柱关节炎患者跟腱和足底筋膜缠绕病的常规放射学检查和相关因素。
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2024-10-28 DOI: 10.4081/reumatismo.2024.1709
Ebru Yılmaz, Özge Pasin

Objective: This study aimed to investigate the correlated risk factors and presence of radiological enthesopathies of the Achilles tendon and plantar fascia in patients with axial spondyloarthropathy (axSpA).

Methods: 242 patients (121 female and 121 male) with axSpA were included in this study. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI), the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP), the Bath Ankylosing Spondylitis Radiology Index (BASRI), the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), and CRP were evaluated in all patients. The lateral foot X-rays of the patients were assessed for enthesopathies of the Achilles tendon and plantar fascia attachments.

Results: Calcaneal spur and Achilles enthesopathies were present in 57.4% of the patients. 39.3% of patients had enthesopathies in both regions. The male and female groups differed statistically in terms of weight, height, body mass index (BMI), positive family history, and duration since diagnosis (p<0.05). The presence of calcaneal spur and Achilles enthesopathies was found to be significantly correlated with age, weight, BMI, symptom duration, and the scores of BASDAI, BASFI, ASDAS-CRP, BASRI, and MASES (p<0.05).

Conclusions: The presence of enthesopathies appears to be associated with age, weight, BMI, symptom duration, and disease activity. Conventional radiography can be used as an auxiliary tool in the evaluation of entheseal abnormalities in patients with SpA, especially in patients with advanced age, long symptom duration, and high BMI.

研究目的本研究旨在探讨轴性脊柱关节病(axSpA)患者跟腱和足底筋膜放射学粘连病变的相关风险因素。对所有患者进行了巴斯强直性脊柱炎疾病活动指数(BASDAI)、巴斯强直性脊柱炎功能指数(BASFI)、强直性脊柱炎疾病活动评分与 C 反应蛋白(ASDAS-CRP)、巴斯强直性脊柱炎放射学指数(BASRI)、马斯特里赫特强直性脊柱炎肌腱炎评分(MASES)和 CRP 评估。对患者足部外侧 X 光片进行了评估,以确定是否存在跟腱和足底筋膜附件的粘连病变:结果:57.4%的患者存在骨骨刺和跟腱粘连病。39.3%的患者同时患有这两个部位的粘连病。男性组和女性组在体重、身高、体重指数(BMI)、阳性家族史和确诊时间方面存在统计学差异(p结论:膝关节病似乎与年龄、体重、体重指数、症状持续时间和疾病活动有关。常规X光检查可作为评估SpA患者腱鞘异常的辅助工具,尤其适用于高龄、症状持续时间长和体重指数(BMI)高的患者。
{"title":"Conventional radiography and correlated factors of enthesopathies of the Achilles tendon and plantar fascia in patients with axial spondyloarthritis.","authors":"Ebru Yılmaz, Özge Pasin","doi":"10.4081/reumatismo.2024.1709","DOIUrl":"10.4081/reumatismo.2024.1709","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the correlated risk factors and presence of radiological enthesopathies of the Achilles tendon and plantar fascia in patients with axial spondyloarthropathy (axSpA).</p><p><strong>Methods: </strong>242 patients (121 female and 121 male) with axSpA were included in this study. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI), the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP), the Bath Ankylosing Spondylitis Radiology Index (BASRI), the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), and CRP were evaluated in all patients. The lateral foot X-rays of the patients were assessed for enthesopathies of the Achilles tendon and plantar fascia attachments.</p><p><strong>Results: </strong>Calcaneal spur and Achilles enthesopathies were present in 57.4% of the patients. 39.3% of patients had enthesopathies in both regions. The male and female groups differed statistically in terms of weight, height, body mass index (BMI), positive family history, and duration since diagnosis (p<0.05). The presence of calcaneal spur and Achilles enthesopathies was found to be significantly correlated with age, weight, BMI, symptom duration, and the scores of BASDAI, BASFI, ASDAS-CRP, BASRI, and MASES (p<0.05).</p><p><strong>Conclusions: </strong>The presence of enthesopathies appears to be associated with age, weight, BMI, symptom duration, and disease activity. Conventional radiography can be used as an auxiliary tool in the evaluation of entheseal abnormalities in patients with SpA, especially in patients with advanced age, long symptom duration, and high BMI.</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review. 接受奥达帕替尼治疗期间普遍性脱发和银屑病关节炎突然好转:基于病例的综述。
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2024-10-25 DOI: 10.4081/reumatismo.2024.1685
Carlo Perricone, Roberto Dal Pozzolo, Giacomo Cafaro, Santina Calvacchi, Lorenza Bruno, Francesco Tromby, Anna Colangelo, Roberto Gerli, Elena Bartoloni

Alopecia universalis (AU), an advanced form of alopecia areata (AA), is a condition characterized by the complete loss of hair over the entire skin surface. Recent progress has significantly enhanced our understanding of the pathogenesis of AU. In particular, interferon-γ (IFN-γ) and interleukin (IL)-15 seem to play a pivotal role in the pathogenesis of the disease. Nonetheless, a variety of medications has been used to treat the disease with frequently inconsistent results. Given the broad modulation of the immune system and inhibition of key molecules, including IFN-γ and IL-15, oral janus kinase (JAK) inhibitors represent a treatment option for moderate to severe cases of AA, as demonstrated in case reports supporting their efficacy and tolerability. We present the case of a patient suffering from psoriatic arthritis and AU who experienced a sudden improvement in peripheral arthritis and AU while receiving JAK1 selective treatment with upadacitinib. So far, there are very limited case reports of successful upadacitinib treatment for patients with AA, mostly in patients also suffering from atopic dermatitis. Thus, we provide evidence for the efficacy of upadacitinib in managing AU in adults, as well as in the context of inflammatory arthritis such as psoriatic arthritis.

普遍性脱发(AU)是斑秃(AA)的一种晚期形式,是一种以整个皮肤表面毛发完全脱落为特征的疾病。最近的研究进展大大提高了我们对普秃发病机制的认识。其中,干扰素-γ(IFN-γ)和白细胞介素(IL)-15似乎在该病的发病机制中起着关键作用。尽管如此,治疗该病的药物种类繁多,但效果往往不尽相同。鉴于口服破伤风激酶(JAK)抑制剂能广泛调节免疫系统并抑制包括 IFN-γ 和 IL-15 在内的关键分子,因此口服破伤风激酶(JAK)抑制剂是治疗中度至重度 AA 病例的一种选择,病例报告证明了其疗效和耐受性。我们介绍了一位患有银屑病关节炎和AU的患者的病例,该患者在接受达帕替尼(upadacitinib)的JAK1选择性治疗后,外周关节炎和AU突然得到改善。迄今为止,有关达帕替尼成功治疗AA患者的病例报道非常有限,其中大多数是同时患有特应性皮炎的患者。因此,我们为达达替尼治疗成人特应性皮炎的疗效提供了证据,而且还适用于银屑病关节炎等炎症性关节炎。
{"title":"Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review.","authors":"Carlo Perricone, Roberto Dal Pozzolo, Giacomo Cafaro, Santina Calvacchi, Lorenza Bruno, Francesco Tromby, Anna Colangelo, Roberto Gerli, Elena Bartoloni","doi":"10.4081/reumatismo.2024.1685","DOIUrl":"10.4081/reumatismo.2024.1685","url":null,"abstract":"<p><p>Alopecia universalis (AU), an advanced form of alopecia areata (AA), is a condition characterized by the complete loss of hair over the entire skin surface. Recent progress has significantly enhanced our understanding of the pathogenesis of AU. In particular, interferon-γ (IFN-γ) and interleukin (IL)-15 seem to play a pivotal role in the pathogenesis of the disease. Nonetheless, a variety of medications has been used to treat the disease with frequently inconsistent results. Given the broad modulation of the immune system and inhibition of key molecules, including IFN-γ and IL-15, oral janus kinase (JAK) inhibitors represent a treatment option for moderate to severe cases of AA, as demonstrated in case reports supporting their efficacy and tolerability. We present the case of a patient suffering from psoriatic arthritis and AU who experienced a sudden improvement in peripheral arthritis and AU while receiving JAK1 selective treatment with upadacitinib. So far, there are very limited case reports of successful upadacitinib treatment for patients with AA, mostly in patients also suffering from atopic dermatitis. Thus, we provide evidence for the efficacy of upadacitinib in managing AU in adults, as well as in the context of inflammatory arthritis such as psoriatic arthritis.</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does the volume of physical exercise influence sleep quality in patients with fibromyalgia? 运动量会影响纤维肌痛患者的睡眠质量吗?
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2024-10-16 DOI: 10.4081/reumatismo.2024.1710
Loiane Cristina De Souza, Guilherme Torres Vilarino, Alexandro Andrade

Objective: To investigate the association between the volume of exercise and the quality of sleep in patients with fibromyalgia.

Methods: This is a cross-sectional study carried out from 2010 to 2019 in patients over 18 years old from the research project at a university in Brazil. Instruments related to sociodemographic and clinical characteristics, physical exercise, and the Pittsburgh Sleep Quality Index (PSQI) were applied. Participants were classified as inactive, insufficiently active, or active. In the statistical analysis, the Kruskal-Wallis and Mann-Whitney U tests were used. Binary logistic and multinomial regression were also performed.

Results: The majority of participants were physically inactive and had poor sleep quality; 68.3% with poor sleep quality were inactive. In the analysis of the difference between the three groups, sleep latency (time it takes to fall asleep) (p=0.00) and total PSQI (p=0.04) were significantly different. When the analysis was performed between active and inactive individuals, significant differences were found in sleep latency (p=0.02), daytime dysfunction (difficulties in performing daytime tasks due to poor sleep quality) (p=0.02), and the total PSQI (p=0.02). Binary logistic regression with crude analysis showed that inactive participants are 4.3 times more likely to have poor sleep quality when compared to active participants (odds ratio = 4.311; 95% confidence interval 1.338-13.888; p=0.014). Multinomial regression analysis showed that being physically active can be a protective factor.

Conclusions: There is a high prevalence of sleep disorders and insufficient practice of physical exercise among patients with fibromyalgia. It is suggested that regular physical exercise may be related to sleep quality, and more active participants have fewer sleep disorders, with exercise being a protective factor.

目的:研究纤维肌痛患者的运动量与睡眠质量之间的关系:研究纤维肌痛患者的运动量与睡眠质量之间的关系:这是一项横断面研究,从 2010 年至 2019 年在巴西一所大学的研究项目中对 18 岁以上的患者进行了研究。研究采用了与社会人口学和临床特征、体育锻炼和匹兹堡睡眠质量指数(PSQI)相关的工具。参与者被分为不活跃、不够活跃和活跃。统计分析采用 Kruskal-Wallis 和 Mann-Whitney U 检验。此外,还进行了二元逻辑回归和多项式回归:大多数参与者缺乏运动,睡眠质量较差;68.3%的睡眠质量较差者缺乏运动。在三组差异分析中,睡眠潜伏期(入睡时间)(P=0.00)和总 PSQI(P=0.04)有显著差异。在对活跃和不活跃人群进行分析时,发现睡眠潜伏期(p=0.02)、日间功能障碍(因睡眠质量差而导致日间工作困难)(p=0.02)和 PSQI 总值(p=0.02)存在显著差异。二元逻辑回归粗分析表明,与活跃的参与者相比,不活跃的参与者睡眠质量差的可能性要高 4.3 倍(几率比 = 4.311;95% 置信区间 1.338-13.888;p=0.014)。多项式回归分析表明,积极参加体育锻炼可以成为一个保护性因素:结论:在纤维肌痛患者中,睡眠障碍和体育锻炼不足的发生率很高。结论:在纤维肌痛患者中,睡眠障碍的发生率很高,而体育锻炼不足则是一个保护因素。有研究表明,经常进行体育锻炼可能与睡眠质量有关,参加体育锻炼越多的患者睡眠障碍越少,而体育锻炼则是一个保护因素。
{"title":"Does the volume of physical exercise influence sleep quality in patients with fibromyalgia?","authors":"Loiane Cristina De Souza, Guilherme Torres Vilarino, Alexandro Andrade","doi":"10.4081/reumatismo.2024.1710","DOIUrl":"10.4081/reumatismo.2024.1710","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the association between the volume of exercise and the quality of sleep in patients with fibromyalgia.</p><p><strong>Methods: </strong>This is a cross-sectional study carried out from 2010 to 2019 in patients over 18 years old from the research project at a university in Brazil. Instruments related to sociodemographic and clinical characteristics, physical exercise, and the Pittsburgh Sleep Quality Index (PSQI) were applied. Participants were classified as inactive, insufficiently active, or active. In the statistical analysis, the Kruskal-Wallis and Mann-Whitney U tests were used. Binary logistic and multinomial regression were also performed.</p><p><strong>Results: </strong>The majority of participants were physically inactive and had poor sleep quality; 68.3% with poor sleep quality were inactive. In the analysis of the difference between the three groups, sleep latency (time it takes to fall asleep) (p=0.00) and total PSQI (p=0.04) were significantly different. When the analysis was performed between active and inactive individuals, significant differences were found in sleep latency (p=0.02), daytime dysfunction (difficulties in performing daytime tasks due to poor sleep quality) (p=0.02), and the total PSQI (p=0.02). Binary logistic regression with crude analysis showed that inactive participants are 4.3 times more likely to have poor sleep quality when compared to active participants (odds ratio = 4.311; 95% confidence interval 1.338-13.888; p=0.014). Multinomial regression analysis showed that being physically active can be a protective factor.</p><p><strong>Conclusions: </strong>There is a high prevalence of sleep disorders and insufficient practice of physical exercise among patients with fibromyalgia. It is suggested that regular physical exercise may be related to sleep quality, and more active participants have fewer sleep disorders, with exercise being a protective factor.</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patients with anti-small ubiquitin-like modifier activating enzyme-positive dermatomyositis resembling antisynthetase syndrome with poor prognosis: a bicentric international retrospective study and literature review. 预后不良的抗小泛素样修饰激活酶阳性皮肌炎患者类似于抗合成酶综合征:一项双中心国际回顾性研究和文献综述。
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2024-10-09 DOI: 10.4081/reumatismo.2024.1686
Camila Gusmão Vicente De Carvalho, Barbara Bayeh, Fernando Henrique Carlos De Souza, Renata Miossi, Pleiades Tiharu Inaoka, Takashi Matsushita, Naoki Mugii, Samuel Katsuyuki Shinjo

Objective: This study aimed to describe adult Brazilian and Japanese patients with anti-small ubiquitin-like modifier activating enzyme (SEA)-positive dermatomyositis (DM), as there are few studies in the literature. A literature review was also conducted.

Methods: This bicentric international retrospective study, conducted between 2012 and 2023, included patients with anti-SAE-positive DM (2017 European League Against Rheumatism/ American College of Rheumatology classification criteria). All demographic features and clinical, laboratory, therapeutic, and follow-up data were collected from Brazilian and Japanese centers using pre-standardized and parameterized information.

Results: We included 17 adult patients with a median age of 65 years (56-76 years) and a predominance of females (82.4%). Constitutional symptoms at baseline were present in 58.8% of the patients. In addition to classical cutaneous DM lesions, one-third of the patients had myalgia and significant muscle weakness, whereas half presented with dysphagia, interstitial lung disease, and joint manifestations. The first-line treatment consisted of intravenous methylprednisolone and immunoglobulin pulse therapy in 41.2% and 28.6% of the patients, respectively. The median follow-up duration was 20 (13-74) months; at the last medical evaluation, half had active disease and were still using oral glucocorticoids (median dosage, 10.0 mg/day). Approximately one-fifth to one-third of the patients were diagnosed with different types of cancer, had severe infections, or died.

Conclusions: Patients with anti-SAE-positive DM not only resemble the phenotype of antisynthetase syndrome but are also associated with a poor prognosis.

研究目的本研究旨在描述抗小泛素样修饰激活酶(SEA)阳性皮肌炎(DM)的巴西和日本成年患者,因为文献中的研究很少。此外,还进行了文献综述:这项双中心国际回顾性研究在2012年至2023年期间进行,纳入了抗SEA阳性DM患者(2017年欧洲抗风湿联盟/美国风湿病学会分类标准)。所有人口统计学特征以及临床、实验室、治疗和随访数据均来自巴西和日本的中心,并使用了预先标准化和参数化的信息:我们共纳入了 17 名成年患者,中位年龄为 65 岁(56-76 岁),女性占多数(82.4%)。58.8%的患者在基线时有全身症状。除了典型的皮肤DM病变外,三分之一的患者还伴有肌痛和明显的肌无力,半数患者出现吞咽困难、间质性肺病和关节表现。分别有41.2%和28.6%的患者接受了静脉甲基强的松龙和免疫球蛋白脉冲治疗。随访时间的中位数为20(13-74)个月;在最后一次医学评估时,半数患者的病情处于活动期,仍在口服糖皮质激素(中位剂量为10.0毫克/天)。约五分之一到三分之一的患者被诊断出患有不同类型的癌症、严重感染或死亡:结论:抗SAE阳性DM患者不仅与抗异烟酸酶综合征的表型相似,而且预后较差。
{"title":"Patients with anti-small ubiquitin-like modifier activating enzyme-positive dermatomyositis resembling antisynthetase syndrome with poor prognosis: a bicentric international retrospective study and literature review.","authors":"Camila Gusmão Vicente De Carvalho, Barbara Bayeh, Fernando Henrique Carlos De Souza, Renata Miossi, Pleiades Tiharu Inaoka, Takashi Matsushita, Naoki Mugii, Samuel Katsuyuki Shinjo","doi":"10.4081/reumatismo.2024.1686","DOIUrl":"10.4081/reumatismo.2024.1686","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to describe adult Brazilian and Japanese patients with anti-small ubiquitin-like modifier activating enzyme (SEA)-positive dermatomyositis (DM), as there are few studies in the literature. A literature review was also conducted.</p><p><strong>Methods: </strong>This bicentric international retrospective study, conducted between 2012 and 2023, included patients with anti-SAE-positive DM (2017 European League Against Rheumatism/ American College of Rheumatology classification criteria). All demographic features and clinical, laboratory, therapeutic, and follow-up data were collected from Brazilian and Japanese centers using pre-standardized and parameterized information.</p><p><strong>Results: </strong>We included 17 adult patients with a median age of 65 years (56-76 years) and a predominance of females (82.4%). Constitutional symptoms at baseline were present in 58.8% of the patients. In addition to classical cutaneous DM lesions, one-third of the patients had myalgia and significant muscle weakness, whereas half presented with dysphagia, interstitial lung disease, and joint manifestations. The first-line treatment consisted of intravenous methylprednisolone and immunoglobulin pulse therapy in 41.2% and 28.6% of the patients, respectively. The median follow-up duration was 20 (13-74) months; at the last medical evaluation, half had active disease and were still using oral glucocorticoids (median dosage, 10.0 mg/day). Approximately one-fifth to one-third of the patients were diagnosed with different types of cancer, had severe infections, or died.</p><p><strong>Conclusions: </strong>Patients with anti-SAE-positive DM not only resemble the phenotype of antisynthetase syndrome but are also associated with a poor prognosis.</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142392913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical utility of lung ultrasound for the detection of interstitial lung disease in patients with rheumatoid arthritis. 肺部超声波在检测类风湿性关节炎患者肺间质疾病方面的临床实用性。
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2024-10-03 DOI: 10.4081/reumatismo.2024.1651
R Tanten Zabaleta, J Marín, J B Zacariaz Hereter, J Maritano, M Fullana, N Alvarado, E R Soriano, J E Rosa

Objective: To establish the diagnostic value of lung ultrasound (LUS) in patients with rheumatoid arthritis (RA) for the detection of interstitial lung disease (ILD).

Methods: A cross-sectional study was performed. Consecutive patients with RA (American College of Rheumatology/European League Against Rheumatism 2010 criteria) who had a chest high-resolution computed tomography (HRCT) performed within 12 months before inclusion, regardless of symptomatology, were included. Demographic, clinical, laboratory, and pharmacological data were recorded. Each patient underwent a LUS with assessment of B-lines (BL) and pleural irregularities (PI). HRCT was considered the gold standard for the confirmatory diagnosis of ILD. Receiver operating characteristic (ROC) curves were calculated to test the ability of LUS findings (BL and PI) in discriminating patients with ILD.

Results: A total of 104 RA patients were included, of which 21.8% had ILD. Patients with ILD had more BL (median 26 versus 1, p<0.001) and PI (median 16 versus 5, p<0.001) than patients without ILD. The diagnostic accuracy in ROC curves was as follows: area under the curve (AUC) 0.88 and 95% confidence interval (CI) 0.78-0.93 for BL and AUC 0.82 and 95% CI 0.74-0.89 for PI. The best cut-off points for (ILD detection) discriminating the presence of significant interstitial lung abnormalities were 8 BL and 7 PI.

Conclusions: The presence of 8 BL and/or 7 PI in the LUS showed an adequate cut-off value for discriminating the presence of significant interstitial lung abnormalities, evocative of ILD.

目的确定肺部超声波(LUS)对类风湿性关节炎(RA)患者间质性肺病(ILD)的诊断价值:进行了一项横断面研究。研究纳入了在纳入前 12 个月内进行过胸部高分辨率计算机断层扫描(HRCT)的连续性类风湿性关节炎患者(美国风湿病学会/欧洲抗风湿病联盟 2010 年标准),无论其症状如何。研究人员记录了患者的人口统计学、临床、实验室和药物学数据。每位患者都接受了LUS检查,评估了B线(BL)和胸膜不规则(PI)。HRCT 被认为是确诊 ILD 的金标准。通过计算接收者操作特征曲线(ROC)来检验 LUS 发现(BL 和 PI)在鉴别 ILD 患者方面的能力:结果:共纳入104名RA患者,其中21.8%患有ILD。ILD患者有更多的BL(中位数为26对1,P结论:LUS中出现8个BL和/或7个PI显示出足够的临界值,可用于鉴别是否存在明显的肺间质异常,从而诱发ILD。
{"title":"Clinical utility of lung ultrasound for the detection of interstitial lung disease in patients with rheumatoid arthritis.","authors":"R Tanten Zabaleta, J Marín, J B Zacariaz Hereter, J Maritano, M Fullana, N Alvarado, E R Soriano, J E Rosa","doi":"10.4081/reumatismo.2024.1651","DOIUrl":"10.4081/reumatismo.2024.1651","url":null,"abstract":"<p><strong>Objective: </strong>To establish the diagnostic value of lung ultrasound (LUS) in patients with rheumatoid arthritis (RA) for the detection of interstitial lung disease (ILD).</p><p><strong>Methods: </strong>A cross-sectional study was performed. Consecutive patients with RA (American College of Rheumatology/European League Against Rheumatism 2010 criteria) who had a chest high-resolution computed tomography (HRCT) performed within 12 months before inclusion, regardless of symptomatology, were included. Demographic, clinical, laboratory, and pharmacological data were recorded. Each patient underwent a LUS with assessment of B-lines (BL) and pleural irregularities (PI). HRCT was considered the gold standard for the confirmatory diagnosis of ILD. Receiver operating characteristic (ROC) curves were calculated to test the ability of LUS findings (BL and PI) in discriminating patients with ILD.</p><p><strong>Results: </strong>A total of 104 RA patients were included, of which 21.8% had ILD. Patients with ILD had more BL (median 26 versus 1, p<0.001) and PI (median 16 versus 5, p<0.001) than patients without ILD. The diagnostic accuracy in ROC curves was as follows: area under the curve (AUC) 0.88 and 95% confidence interval (CI) 0.78-0.93 for BL and AUC 0.82 and 95% CI 0.74-0.89 for PI. The best cut-off points for (ILD detection) discriminating the presence of significant interstitial lung abnormalities were 8 BL and 7 PI.</p><p><strong>Conclusions: </strong>The presence of 8 BL and/or 7 PI in the LUS showed an adequate cut-off value for discriminating the presence of significant interstitial lung abnormalities, evocative of ILD.</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142366390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Reumatismo
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1